Alpha-1 肺部疾病市場（依疾病類型、治療類型、給藥途徑、通路及地區分類）

Alpha 1 Lung Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Region

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Alpha-1 肺部疾病市場規模預計在 2025 年為 70.5 億美元，預計到 2032 年將達到 236.8 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 18.9%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	70.5億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	18.90%	2032年價值預測	236.8億美元

α-1肺病是一種罕見的遺傳性疾病，會影響肺部和肝臟。此病是由α-1抗胰蛋白酶（AAT）缺乏所引起，AAT是一種保護肺部免受損傷的蛋白質。這種疾病可能導致慢性阻塞性肺病（COPD）和肝病。

全球α-1型肺病市場的發展受到盛行率上升、醫療專業人員認知度提升、診斷技術進步的驅動。根據α-1基金會估計，美國和歐洲約有10萬人被診斷為α-1型肺病。然而，實際患病人數據信件要高得多。

市場動態：

Alpha-1型肺部疾病市場的主要驅動力在於盛行率的上升。隨著越來越多的患者被診斷出患有Alpha-1型肺部疾病，對有效治療方案的需求也日益成長。這促使市場主要參與者加強研發力道。

然而，有幾個因素制約了市場的成長：一般民眾和醫務人員對疾病的認知程度低，阻礙了早期診斷和治療，治療費用高以及某些地區缺乏報銷政策，對市場成長構成了挑戰。

儘管面臨諸多挑戰，市場仍蘊含著許多成長機會。基因檢測等診斷技術的進步有望提高早期檢測率。此外，新型治療藥物和標靶藥物的開發也為α-1型肺病的治療帶來了希望。

例如，2022年6月，美國食品藥物管理局（FDA）的藥品評估與食品藥物管理局中心（CDER）和生技藥品評估與研究中心（CBER）——美國國家中心——將宣布計劃與生物製藥關鍵路徑研究所（C-Path）合作，成立一個聯盟，旨在開發適用於α-1抗胰蛋白酶缺乏症（AATD）臨床開發項目，成立一個聯盟，旨在開發適用於α-125,D55（AATD）臨床開發項目，導致肺移植會導致肺臟移植會進行性破壞疾病，導致肺臟移植會導致肺臟移植會導致肺臟移植是一種罕見疾病，導致肺臟移植會導致肺臟移植會導致肺臟移植會導致肺臟移植會導致肺臟移植是一種罕見疾病（AATD）臨床開發項目。

本研究的主要特點

本報告對全球 alpha-1 肺部疾病市場進行了詳細分析，包括預測期 2025-2032 的市場規模和年複合成長率。
它揭示了各個領域的潛在收益成長機會，並說明了該市場引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
這項研究涉及的主要企業包括阿斯特捷利康、勃林格殷格翰國際有限公司、羅氏有限公司、諾華公司、輝瑞公司、默克公司、百時美施貴寶公司、武田製藥有限公司、傑特貝林公司、Vertex Pharmaceuticals Incorporated、安進公司、賽諾菲公司、葛蘭素史克公司、吉利德科學公司、艾伯維科公司等公司。
本報告的見解將幫助負責人和經營團隊就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
全球 Alpha-1 肺部疾病市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球 Alpha-1 肺部疾病市場的各種策略矩陣來更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 7.05 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	18.90%	2032 Value Projection:	USD 23.68 Bn

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

By Disease Type
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Bronchiectasis
- Others
By Treatment Type
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Lung Transplantation
- Others
By Route of Administration
- Injectable
- Oral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.,
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Alpha 1 Lung Disease, By Disease Type
- Market Alpha 1 Lung Disease, By Treatment Type
- Market Alpha 1 Lung Disease, By Route of Administration
- Market Alpha 1 Lung Disease, By Distribution Channel
- Market Alpha 1 Lung Disease, By Region
Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising Prevalence of COPD Globally
Increasing Diagnosis Rates
New Product Launches
Strong Pipeline of Drugs
- Restraints
Limited awareness about the disease among the general population
- Opportunities
Technological advancements in diagnostic techniques
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Alpha-1 Antitrypsin Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Bronchiectasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Augmentation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oxygen Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Lung Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views